Osteoporosis in postmenopausal women: Therapy options across a wide range of risk for fracture

Research output: Contribution to journalArticle

Abstract

Osteoporosis is a highly prevalent skeletal disorder characterized by compromised bone strength predisposing individuals to an increased risk of fractures. Fractures related to osteoporosis are frequently associated with chronic pain and decreased quality of life, as well as significant morbidity and mortality. Postmenopausal women are at higher risk for developing osteoporosis and osteoporosis-related fractures. Osteoporotic fractures are commonly asymptomatic, necessitating a need for proactive screening, diagnostic testing, and more importantly, therapeutic intervention that will rapidly reduce the risk of fractures in at-risk patients. Current pharmacologic prevention and treatment options for osteoporosis include antiresorptive therapies (alendronate, risedronate, ibandronate, raloxifene, hormone therapy, and calcitonin) and the anabolic agent teriparatide.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalGeriatrics
Volume61
Issue number1
StatePublished - Jan 2006

Fingerprint

Postmenopausal Osteoporosis
Osteoporosis
Teriparatide
Therapeutics
Anabolic Agents
Alendronate
Osteoporotic Fractures
Calcitonin
Chronic Pain
Quality of Life
Hormones
Morbidity
Bone and Bones
Mortality

Keywords

  • Bisphosphonates
  • Osteoporosis
  • Osteoporotic fractures
  • Postmenopausal

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Osteoporosis in postmenopausal women : Therapy options across a wide range of risk for fracture. / Miller, Redonda.

In: Geriatrics, Vol. 61, No. 1, 01.2006, p. 24-30.

Research output: Contribution to journalArticle

@article{609a391dfbee4ca3b74f572914e47d4e,
title = "Osteoporosis in postmenopausal women: Therapy options across a wide range of risk for fracture",
abstract = "Osteoporosis is a highly prevalent skeletal disorder characterized by compromised bone strength predisposing individuals to an increased risk of fractures. Fractures related to osteoporosis are frequently associated with chronic pain and decreased quality of life, as well as significant morbidity and mortality. Postmenopausal women are at higher risk for developing osteoporosis and osteoporosis-related fractures. Osteoporotic fractures are commonly asymptomatic, necessitating a need for proactive screening, diagnostic testing, and more importantly, therapeutic intervention that will rapidly reduce the risk of fractures in at-risk patients. Current pharmacologic prevention and treatment options for osteoporosis include antiresorptive therapies (alendronate, risedronate, ibandronate, raloxifene, hormone therapy, and calcitonin) and the anabolic agent teriparatide.",
keywords = "Bisphosphonates, Osteoporosis, Osteoporotic fractures, Postmenopausal",
author = "Redonda Miller",
year = "2006",
month = "1",
language = "English (US)",
volume = "61",
pages = "24--30",
journal = "Geriatrics",
issn = "0016-867X",
publisher = "Advanstar Communications",
number = "1",

}

TY - JOUR

T1 - Osteoporosis in postmenopausal women

T2 - Therapy options across a wide range of risk for fracture

AU - Miller, Redonda

PY - 2006/1

Y1 - 2006/1

N2 - Osteoporosis is a highly prevalent skeletal disorder characterized by compromised bone strength predisposing individuals to an increased risk of fractures. Fractures related to osteoporosis are frequently associated with chronic pain and decreased quality of life, as well as significant morbidity and mortality. Postmenopausal women are at higher risk for developing osteoporosis and osteoporosis-related fractures. Osteoporotic fractures are commonly asymptomatic, necessitating a need for proactive screening, diagnostic testing, and more importantly, therapeutic intervention that will rapidly reduce the risk of fractures in at-risk patients. Current pharmacologic prevention and treatment options for osteoporosis include antiresorptive therapies (alendronate, risedronate, ibandronate, raloxifene, hormone therapy, and calcitonin) and the anabolic agent teriparatide.

AB - Osteoporosis is a highly prevalent skeletal disorder characterized by compromised bone strength predisposing individuals to an increased risk of fractures. Fractures related to osteoporosis are frequently associated with chronic pain and decreased quality of life, as well as significant morbidity and mortality. Postmenopausal women are at higher risk for developing osteoporosis and osteoporosis-related fractures. Osteoporotic fractures are commonly asymptomatic, necessitating a need for proactive screening, diagnostic testing, and more importantly, therapeutic intervention that will rapidly reduce the risk of fractures in at-risk patients. Current pharmacologic prevention and treatment options for osteoporosis include antiresorptive therapies (alendronate, risedronate, ibandronate, raloxifene, hormone therapy, and calcitonin) and the anabolic agent teriparatide.

KW - Bisphosphonates

KW - Osteoporosis

KW - Osteoporotic fractures

KW - Postmenopausal

UR - http://www.scopus.com/inward/record.url?scp=31144466851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144466851&partnerID=8YFLogxK

M3 - Article

C2 - 16405361

AN - SCOPUS:31144466851

VL - 61

SP - 24

EP - 30

JO - Geriatrics

JF - Geriatrics

SN - 0016-867X

IS - 1

ER -